Research & KnowledgeEvent: September 8, 2026
Baseimmune reported 12-month interim data from a Phase 1b/2 trial of ACI-24, an anti-amyloid beta active immunotherapy manufactured antibodies.
Published
Signal category
Research & Knowledge
Quote
“Back in June, AC Immune reported 12-month interim data from Phase 1b/2 trial of ACI-24, an anti-amyloid beta ACTIVE IMMUNOTHERAPY”
— Joshua Blight|Baseimmune team
Company
Baseimmune
Pioneering the next generation of active immunotherapies for chronic diseases
- Industry
- Biotechnology Research
- Location
- London, GB
- Company size
- 28 employees
Baseimmune was founded in 2019 as a discovery phase start-up in the antigen discovery and vaccine development field.
Founded 2019